Improving data translatability between preclinical testing and clinical applications is crucial for advancing drug safety assessment. A major challenge lies in enhancing the predictivity of standard toxicology workflows to better identify complex or species-specific toxicity risks. In this webinar, Emily Richardson will describe how liver microphysiological systems (MPS), also called liver-on-a-chip technology, can improve safety testing by providing greater physiological relevance, longevity, and cross-species insights to support research decisions and therapeutic development.
Topics to be covered:
- Addressing workflow limitations with the routine use of human liver MPS in toxicology testing
- Overcoming drug development challenges with insights provided by liver MPS
- Leveraging species-specific MPS and mechanistic endpoints to improve data translatability and prevent misclassification of drugs
Session 1: Tuesday, May 13th, 2025 | 11:00 AM - 12:00 PM Eastern Time
Session 2: Wednesday, May 14th, 2025 | 5:00 PM - 6:00 PM Eastern Time
This webinar will be available to view live and on demand.
Rhiannon Hardwick, PhD, DABT
Scientific Associate Director, Discovery Toxicology
Bristol Myers Squibb
.png "Emily Richardson, PhD")
Emily Richardson, PhD
Lead Scientist
CN Bio
Tomasz Kostrzewski, PhD
Chief Scientific Officer
CN Bio
